Abstract 4671

Introduction:

VerifyNow P2Y12 is commonly used to measure responsiveness to clopidogrel. We sought to compare the results obtained from novel INNOVANCE® PFA P2Y and VerifyNow P2Y12 assay for the assessment of clopidogrel resistance in patients with undergoing percutaneous coronary intervention.

Methods:

255 patients undergoing percutaneous coronary intervention, preliminarily treated with 100 mg/day of aspirin followed co- administration of clopidogrel(loading dose 600 mg, maintenance dose 75 mg/day), were enrolled in this study. Platelet aggregation was measured by INNOVANCE® PFA P2Y and VerifyNow P2Y12.

Results:

INNOVANCE® PFA P2Y and VerifyNow P2Y12 assay showed moderate correlations with INNOVANCE® PFA P2Y Vs VerifyNow %inhibition: r = 0.412, p < 0.0001; INNOVANCE® PFA P2Y Vs VerifyNow platelet reactivity units(PRU): r = −0.402, p < 0.0001. The agreement between INNOVANCE® PFA P2Y and VerifyNow %inhibition was 85 % and that of INNOVANCE® PFA P2Y and VerifyNow platelet reactivity units(PRU) was 79%: The k statistics between INNOVANCE® PFA P2Y and VerifyNow %inhibition and platelet reactivity units(PRU) were 0.52 and 0.44, respectively.

Conclusions:

INNOVANCE® PFA P2Y’s sensitivity in detecting clopidogrel resistance is comparable to VerifyNow P2Y12 assay. As the PFA-100® system was already widely used, the new test cartilage may be useful tool for the assessment of clopidogrel effects. Additional Clinical correlation studies were required to validate the effectiveness of INNOVANCE® PFA P2Y for predicting long term clinical outcomes.

Disclosures:

No relevant conflicts of interest to declare.

Topics:
clopidogrel, percutaneous coronary intervention, receptors, purinergic p2y12, aspirin, drug loading dose, drug maintenance dose, platelet aggregation, treatment outcome, blood platelets, cartilage

Author notes

*

Asterisk with author names denotes non-ASH members.

© 2011 by The American Society of Hematology
2011
Sign in via your Institution